Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

PHASE2CompletedINTERVENTIONAL
Enrollment

507

Participants

Timeline

Start Date

November 16, 2022

Primary Completion Date

May 16, 2024

Study Completion Date

June 14, 2025

Conditions
ObesityObeseOverweight or Obesity
Interventions
BIOLOGICAL

Bimagrumab

Human monoclonal antibody to the activin receptor type II

DRUG

Semaglutide

Glucagon-like peptide-1 (GLP-1) receptor agonist

OTHER

Placebo

Placebo

Trial Locations (26)

1010

New Zealand Clinical Research Auckland, Auckland

Optimal Clinical Trials, Auckland

2025

Middlemore Hospital, Auckland

2065

Royal North Shore Hospital, Saint Leonards

2100

Northern Beaches Clinical Research, Brookvale

3081

Austin Health, Heidelberg Heights

3124

Emeritus Research, Camberwell

3200

Lakeland Clinical Trials Waikato, Hamilton

4101

University of The Sunshine Coast South Brisbane, South Brisbane

4215

Gold Coast University Hospital, Southport

4506

University of The Sunshine Coast Morayfield, Morayfield

6242

P3 Research, Newtown

7011

Southern Clinical Trials Tasman, Nelson

8011

New Zealand Clinical Research Christchurch, Christchurch

8013

Southern Clinical Trials Ltd, Beckenham, Christchurch

10021

Weill Cornell Medical College, New York

28112

Monroe Biomedical Research, Monroe

29322

SPICA Clinical, Columbia

32256

Clinical Neuroscience Solutions Inc, Jacksonville

33012

Indago Research & Health Center, Inc, Hialeah

33461

Altus Research, Lake Worth

35055

Cullman Clinical Trials, Cullman

36207

Pinnacle Research Group, LLC, Anniston

70808

Pennington Biomedical Research Center, Baton Rouge

77479

Mt. Olympus Medical Research, Sugar Land

04556

University of the Sunshine Coast Clinical Trial Centre, Sippy Downs

All Listed Sponsors
collaborator

Versanis Bio, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY